2008 french national guidelines for the treatment of venous thromboembolism in patients with cancer: Report from the working group

被引:66
作者
Farge, Dominique [1 ,2 ,3 ]
Bosquet, Lise
Kassab-Chahmi, Diana
Mismetti, Patrick [4 ]
Elalamy, Ismail [5 ]
Meyer, Guy [6 ]
Cajfinger, Francis [7 ]
Desmurs-Clavel, Helene [8 ]
Elias, Antoine [9 ]
Grange, Claire [10 ]
Hocini, Hamid
Legal, Gregoire [11 ]
Mahe, Isabelle [12 ]
Quere, Isabelle [13 ]
Levesque, Herve [14 ]
Debourdeau, Philippe [15 ]
机构
[1] Natl Canc Inst, Dept Recommandat, F-92513 Boulogne, France
[2] Hop St Louis, Serv Med Interne & Pathol Vasc, AP HP, Paris, France
[3] Univ Paris 07, INSERM, U976, F-75221 Paris 05, France
[4] Hop Nord St Etienne, St Etienne, France
[5] Hop Tenon, F-75970 Paris, France
[6] Hop Georges Pompidou, Paris, France
[7] Hop La Pitie Salpetriere, Paris, France
[8] Hop Edouard Herriot, Lyon, France
[9] Hop Font Pre, Toulon, France
[10] Hop Lyon Sud, Lyon, France
[11] Hop Cavale Blanche, Brest, France
[12] Hop Louis Mourier, F-92701 Colombes, France
[13] Hop St Eloi, Montpellier, France
[14] Hop Bois Guillaume, Rouen, France
[15] Hop Armees Desgenettes, Lyon, France
关键词
Cancer; Clinical practice guidelines; Low-molecular-weight heparins; Thrombolytics; Unfractionated heparin; Vena cava filters; Venous thromboembolism; Vitamin K antagonists; MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; VENA-CAVAL FILTERS; HIGH-GRADE GLIOMAS; PULMONARY-EMBOLISM; UNFRACTIONATED HEPARIN; ORAL ANTICOAGULANTS; ANTITHROMBOTIC THERAPY; SECONDARY PREVENTION; MALIGNANT-DISEASE;
D O I
10.1016/j.critrevonc.2008.12.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Venous thromboembolism (VTE) is a major therapeutic issue in cancer patients. Advances in this field and heterogeneities in clinical practices prompted us to establish guidelines in the management of WE in cancer patients according to the SOR (Standards, Options and Recommendations) methodology. A literature review of the studies published on this topic between 1999 and 2007 was performed. The guidelines were developed from the analysis of 38 out of 418 publications selected. They were peer-reviewed by 65 independent experts. The treatment of WE in patients with cancer, including those with intracranial malignancies, should be based on low-molecular-weight heparins administered at therapeutic doses for at least 3 months. In the event of recurrent VTE, pulmonary embolism with hemodynamic failure or contra-indication to anticoagulant treatment, the indications and usages of vena cava filters and thrombolytic drugs should be the same as in non-cancer patients. (C) 2009 Dominique Farge. Published by Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:31 / 46
页数:16
相关论文
共 71 条
[1]   Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer [J].
Akl, E. A. ;
Barba, M. ;
Rohilla, S. ;
Terrenato, I ;
Sperati, F. ;
Muti, P. ;
Schuenemann, H. J. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (02)
[2]   Anticoagulation for the intial treatment of venous thromboembolism in patients with cancer [J].
Akl, E. A. ;
Rohilla, S. ;
Barba, M. ;
Sperati, F. ;
Terrenato, I ;
Muti, P. ;
Schunemann, H. J. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (01)
[3]   Venous thromboembolism in patients with colorectal cancer: Incidence and effect on survival [J].
Alcalay, A ;
Wun, T ;
Khatri, V ;
Chew, HK ;
Harvey, D ;
Zhou, H ;
White, RH .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1112-1118
[4]   Risk factors for venous thromboembolism in hospitalized patients with acute medical illness - Analysis of the MEDENOX study [J].
Alikhan, R ;
Cohen, AT ;
Combe, S ;
Samama, MM ;
Desjardins, L ;
Eldor, A ;
Janbon, C ;
Leizorovicz, A ;
Olsson, CG ;
Turpie, AGG .
ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (09) :963-968
[5]   THE RISK AND EFFICACY OF ANTICOAGULANT-THERAPY IN THE TREATMENT OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH PRIMARY MALIGNANT BRAIN-TUMORS [J].
ALTSCHULER, E ;
MOOSA, H ;
SELKER, RG ;
VERTOSICK, FT .
NEUROSURGERY, 1990, 27 (01) :74-77
[6]   Warfarin is safe as secondary prophylaxis in patients with cancer and a previous episode of venous thrombosis [J].
Bona, RD ;
Hickey, AD ;
Wallace, DM .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (01) :71-73
[7]   Antithrombotic therapy for venous thromboembolic disease [J].
Büller, HR ;
Agnelli, G ;
Hull, RD ;
Hyers, TA ;
Prins, AH ;
Raskob, GE .
CHEST, 2004, 126 (03) :401S-428S
[8]  
Calligaro K D, 1991, Ann Vasc Surg, V5, P186, DOI 10.1007/BF02016754
[9]   COMPLICATIONS AND FAILURE OF ANTICOAGULATION THERAPY IN THE TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH DISSEMINATED MALIGNANCY [J].
CHAN, A ;
WOODRUFF, RK .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1992, 22 (02) :119-122
[10]  
CHERUKU R, 1991, CANCER, V68, P2621, DOI 10.1002/1097-0142(19911215)68:12<2621::AID-CNCR2820681218>3.0.CO